Top

Published in:

01-04-2010 | Case Report

Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease

Authors: Ashley Sumrall, Ruth Fredericks, Anne Berthold, Grace Shumaker

Published in: Journal of Neuro-Oncology | Issue 2/2010

Abstract

Epithelioid Hemangioendothelioma (EH) is a rare soft-tissue tumor which may present as an isolated tumor or can spread to affect internal organs. The course of EH varies, based on the tissue of origin. This case report describes a young woman who developed cutaneous EH with concurrent intracranial disease during pregnancy. After resection, the lesions returned. Even after several courses of chemotherapy and radiotherapy, the patient developed multifocal disease including pulmonary, skeletal, and liver disease. She now exhibits stable disease after approximately 6 years of therapy with lenalidomide.

Fenniche S, Benmously R, Marrak H et al (2004) Cutaneous epithelioid hemangioendothelioma. Ann Dermatol Venereol 131(8–9):818–821CrossRefPubMed

Puca A, Meglio M, Massimo R et al (1996) Intracranial epithelioid hemangioendothelioma: case report. Neurosurger 38(2):399–401CrossRef

Fernandes A, Ratilal B, Mafra M et al (2006) Aggressive intracranial and extracranial epithelioid hemangioendothelioma: a case report and review of the literature. Neuropathology 26(3):201–205CrossRefPubMed

Bollinger B, Laskin W, Knight C (1994) Epithelioid hemangioendothelioma with multiple site involvement: literature review and observations. Cancer 73:610–615CrossRefPubMed

Tsuneyoshi M, Dorfman H, Bauer T (1986) Epithelioid hemangioendothelioma of bone: a clinicopathologic, ultrastructural, and immunohistochemical study. Am J Surg Pathol 10:754–756CrossRefPubMed

Miller A, Case D, Harmon M (2007) Phase I Study of lenalidomide in solid tumors. J Thorac Oncol 5:445–449CrossRef

Mascarenhas R, Sanghvi A, Friedlander L et al (2004) Thalidomide inhibits the growth and progression of hepatic epithelioid hemangioendothelioma. Oncology 67:471–475CrossRefPubMed

Kalmadi S, Baz R, Mahindra A (2007) Lenalidomide: the emerging role of a novel targeted agent in malignancies. Drugs Today 43(2):85–95CrossRefPubMed

Kastritis E, Dimopoulos M (2007) The evolving role of lenalidomide in the treatment of hematologic malignancies. Expert Opin Pharmacother 8(4):497–509CrossRefPubMed

10.

Bartlett J, Michael A, Clarke I et al (2004) Phase I study to determine the safety, tolerability, and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic melanoma and other advanced cancers. Br J Cancer 90(5):955–961CrossRefPubMed

Title: Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease
Authors: Ashley Sumrall
Ruth Fredericks
Anne Berthold
Grace Shumaker
Publication date: 01-04-2010
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2010
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-009-0017-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Pituitary metastasis of Merkel cell carcinoma

The cell growth inhibitory transcription factor C/EBPδ is expressed in human meningiomas in association with low histological grade and proliferation index

Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate

Clinical and epidemiological characteristics of pediatric gliosarcomas

Central nervous system involvement in CD4+/CD56+ hematodermic neoplasm: a report of two cases

Immunotherapy of pediatric brain tumor patients should include an immunoprevention strategy: a medical hypothesis paper